SEC Company Response from Opus Genetics, Inc. (IRD) (CIK 0001228627) (IRD) — Oct 1, 2010
Opus Genetics, Inc. (IRD) (CIK 0001228627)
Date: Oct. 1, 2010 · CIK: 0001228627 · Accession: 0001140361-10-039251
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-34079
Referenced dates: September 17, 2010
Letter
Division of Corporation Finance Rexahn Pharmaceuticals, Inc. Form 10-K for the year ended December 31, 2009 Schedule 14A filed April 26, 2010 File No. 001-34079
Dear Ms. Nakada:
On behalf of Rexahn Pharmaceuticals, Inc. (the “Company”), we hereby request that the Staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) grant the Company an extension for filing its response to the Staff’s comments regarding the above referenced Annual Report on Form 10-K for the year ended December 31, 2009 (“Form 10-K”) and Schedule 14A filed on April 26, 2010 (“Schedule 14A”) contained in the Staff’s letter to Dr. Chang Ahn dated September 17, 2010. The Company expects to file its response to the Staff’s comments on the Form 10-K and Schedule 14A on or before October 15, 2010.
The Company thanks you for your consideration of the requested extension and is available to answer any questions you may have.
Respectfully submitted,
/s/Hwan Kim
Show Raw Text
CORRESP
1
filename1.htm
corresp.htm
2550 M Street NW
Washington DC 20037
(202) 457-6000
__________
Facsimile (202) 457-6315
October 1, 2010
Hwan Kim
202-457-8025
HKim@pattonboggs.com
Ms. Keira Nakada
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
Re:
Rexahn Pharmaceuticals, Inc.
Form 10-K for the year ended December 31, 2009
Schedule 14A filed April 26, 2010
File No. 001-34079
Dear Ms. Nakada:
On behalf of Rexahn Pharmaceuticals, Inc. (the “Company”), we hereby request that the Staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) grant the Company an extension for filing its response to the Staff’s comments regarding the above referenced Annual Report on Form 10-K for the year ended December 31, 2009 (“Form 10-K”) and Schedule 14A filed on April 26, 2010 (“Schedule 14A”) contained in the Staff’s letter to Dr. Chang Ahn dated September 17, 2010. The Company expects to file its response to the Staff’s comments on the Form 10-K and Schedule 14A on or before October 15, 2010.
The Company thanks you for your consideration of the requested extension and is available to answer any questions you may have.
Respectfully submitted,
/s/Hwan Kim
Hwan Kim